文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.

作者信息

Zent Clive S, Elliott Michael R

机构信息

Wilmot Cancer Institute, University of Rochester Medical Center, NY, USA.

Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, NY, USA.

出版信息

FEBS J. 2017 Apr;284(7):1021-1039. doi: 10.1111/febs.13961. Epub 2016 Nov 29.


DOI:10.1111/febs.13961
PMID:27863012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5378628/
Abstract

The phagocytic clearance of host cells is important for eliminating dying cells and for the therapeutic clearance of antibody-targeted cells. As ubiquitous, motile and highly phagocytic immune cells, macrophages are principal players in the phagocytic removal of host cells throughout the body. In recent years, great strides have been made in identifying the molecular mechanisms that control the recognition and phagocytosis of cells by macrophages. However, much less is known about the physical and metabolic constraints that govern the amount of cellular material macrophages can ingest and how these limitations affect the overall efficiency of host cell clearance in health and disease. In this review we will discuss, in the contexts of apoptotic cells and antibody-targeted malignant cells, how physical and metabolic factors associated with the internalization of host cells are relayed to the phagocytic machinery and how these signals can impact the overall efficiency of cell clearance. We also discuss how this information can be leveraged to increase cell clearance for beneficial therapeutic outcomes.

摘要

相似文献

[1]
Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.

FEBS J. 2017-4

[2]
ArhGAP12 plays dual roles in Stabilin-2 mediated efferocytosis: Regulates Rac1 basal activity and spatiotemporally turns off the Rac1 to orchestrate phagosome maturation.

Biochim Biophys Acta Mol Cell Res. 2019-7-10

[3]
M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.

J Immunol. 2009-4-1

[4]
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.

Int J Oncol. 2011-10-21

[5]
Peptidoglycan Suppresses Phagocytic Activities and Apoptosis of Macrophages in Colonic Mucosa Tissues of Crohn's Disease Patients and In Vitro.

Med Sci Monit. 2018-5-22

[6]
Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.

J Immunol. 2015-7-15

[7]
Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance.

Blood. 2020-10-29

[8]
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance.

Nature. 2009-9-10

[9]
Photo-enhancement of macrophage phagocytic activity via Rac1-mediated signaling pathway: Implications for bacterial infection.

Int J Biochem Cell Biol. 2016-9

[10]
Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis.

Biochem Pharmacol. 2013-7-12

引用本文的文献

[1]
Measurement of macrophage phagocytic capacity by quantifying maximum membrane extension using an opsonized capillary tube assay.

Sci Rep. 2025-5-30

[2]
Electroactive Electrospun Nanofibrous Scaffolds: Innovative Approaches for Improved Skin Wound Healing.

Adv Sci (Weinh). 2025-5

[3]
Biochemical and biophysical mechanisms macrophages use to tune phagocytic appetite.

J Cell Sci. 2025-1-1

[4]
A multiscale model of immune surveillance in micrometastases gives insights on cancer patient digital twins.

NPJ Syst Biol Appl. 2024-12-4

[5]
Impact of Viral Lower Respiratory Tract Infection (LRTI) in Early Childhood (0-2 Years) on Lung Growth and Development and Lifelong Trajectories of Pulmonary Health: A National Institutes of Health (NIH) Workshop Summary.

Pediatr Pulmonol. 2025-1

[6]
Prior Fc receptor activation primes macrophages for increased sensitivity to IgG via long-term and short-term mechanisms.

Dev Cell. 2024-11-4

[7]
A Lipid-Structured Model of Atherosclerosis with Macrophage Proliferation.

Bull Math Biol. 2024-7-9

[8]
Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials.

J Pers Med. 2024-3-29

[9]
Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies.

Science. 2024-1-19

[10]
Insect-pathogen crosstalk and the cellular-molecular mechanisms of insect immunity: uncovering the underlying signaling pathways and immune regulatory function of non-coding RNAs.

Front Immunol. 2023

本文引用的文献

[1]
Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies.

Sci Rep. 2016-10-4

[2]
Clearance of apoptotic neutrophils and resolution of inflammation.

Immunol Rev. 2016-9

[3]
Noncanonical autophagy inhibits the autoinflammatory, lupus-like response to dying cells.

Nature. 2016-5-5

[4]
Boosting Apoptotic Cell Clearance by Colonic Epithelial Cells Attenuates Inflammation In Vivo.

Immunity. 2016-4-19

[5]
The clearance of dying cells: table for two.

Cell Death Differ. 2016-6

[6]
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer.

Cell Death Differ. 2016-6

[7]
Macrophage Phenotype and Function in Different Stages of Atherosclerosis.

Circ Res. 2016-2-19

[8]
Erythropoeitin Signaling in Macrophages Promotes Dying Cell Clearance and Immune Tolerance.

Immunity. 2016-2-9

[9]
Apoptotic cell recognition receptors and scavenger receptors.

Immunol Rev. 2016-1

[10]
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Am J Hematol. 2016-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索